Soluble Fas ligand (sFasL) strongly inhibits migration and chemotaxis of endothelial cells (ECs)

<p><b>Copyright information:</b></p><p>Taken from "Soluble Fas ligand inhibits angiogenesis in rheumatoid arthritis"</p><p>http://arthritis-research.com/content/9/2/R42</p><p>Arthritis Research & Therapy 2007;9(2):R42-R42.</p><p>Published online 26 Apr 2007</p><p>PMCID:PMC1906820.</p><p></p> Inhibition of wounding migration of ECs by sFasL. Confluent ECs were wounded with the tip of a micropipette, and incubated further in M199 containing 1% FCS with vascular endothelial growth factor (VEGF)(20 ng/ml) in the absence or presence of sFasL (50 ng/ml). After 12 hours, the cells migrating beyond the reference line were photographed (at ×50 magnification) and counted. A representative of three independent experiments is shown. sFasL suppresses the chemotaxis of ECs induced by VEGF. The ECs were placed in the upper wells of the chemotaxis chamber with various concentrations (0.1 to 100 ng/ml) of soluble CD40 ligand (sCD40L) or sFasL in the presence of VEGF (10 ng/ml) added in the lower wells. The number of cells that had migrated to the lower surface of the membrane was counted after hematoxylin and eosin staining. Data are representative of three independent experiments, presented as the mean ± standard deviation. < 0.01 versus the VEGF-stimulated cells without sFasL